Promising drug combo targets Hard-to-Treat amyloidosis
NCT ID NCT05451771
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, venetoclax and dexamethasone, in people with a rare blood disorder called AL amyloidosis that has come back or not improved after treatment. The trial includes 53 adults with a specific genetic marker (t(11;14)). The goal is to find the safest dose and see how well the drugs work at reducing abnormal proteins and improving organ function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax (Venclexta) and dexamethasone
- What this could lead to
- If successful, this could offer a new treatment option for people with a specific genetic type of AL amyloidosis that has not responded to prior therapy.
- What could go wrong
- This is an early-phase trial with only 53 participants, so results may not apply broadly. Side effects like low blood counts and tumor lysis syndrome are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
New York Presbyterian Hospital/Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Nationwide registry aims to crack the code of a rare protein-clogging disease
- New scan spots hidden organ damage before symptoms start
- Could a simple scan unlock better heart treatment?